PacBio Files Additional Proxy Materials
Ticker: PACB · Form: DEFA14A · Filed: May 30, 2024 · CIK: 1299130
Sentiment: neutral
Topics: sec-filing, proxy-statement, shareholder-materials
TL;DR
PacBio dropped more shareholder info, no fee paid.
AI Summary
Pacific Biosciences of California, Inc. (PacBio) filed a Definitive Additional Materials (DEFA14A) on May 30, 2024. This filing relates to the company's proxy statement and does not involve a fee, as indicated by the 'No fee required' checkbox. The document is a standard filing for public companies to provide additional materials to shareholders.
Why It Matters
This filing indicates that Pacific Biosciences is providing supplementary information to its shareholders, likely related to upcoming corporate actions or annual meetings, which is crucial for shareholder engagement and voting.
Risk Assessment
Risk Level: low — This is a routine SEC filing for additional proxy materials and does not inherently present new risks.
Key Players & Entities
- PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (company) — Registrant
- 0001299130-24-000127 (filing_id) — Accession Number
- 20240530 (date) — Filing Date
FAQ
What type of SEC filing is this?
This is a DEFA14A, which signifies Definitive Additional Materials filed with the SEC.
Who is the filing company?
The filing company is Pacific Biosciences of California, Inc.
When was this filing made?
The filing was made on May 30, 2024.
Is there a fee associated with this filing?
No, the filing explicitly states 'No fee required'.
What is the purpose of a DEFA14A filing?
A DEFA14A filing is used to provide additional materials to shareholders related to a proxy statement, often after the initial preliminary filing.
Filing Stats: 114 words · 1 min read · ~1 pages · Grade level 15.2 · Accepted 2024-05-29 21:52:04
Filing Documents
- a2024defa14a-additionalmat.htm (DEFA14A) — 14KB
- a2024_annualxshareholderxmn.jpg (GRAPHIC) — 362KB
- a2024_annualxshareholderxmo.jpg (GRAPHIC) — 297KB
- a2024_annualxshareholderxmp.jpg (GRAPHIC) — 254KB
- a2024_annualxshareholderxmq.jpg (GRAPHIC) — 129KB
- a2024_annualxshareholderxmr.jpg (GRAPHIC) — 91KB
- a2024_annualxshareholderxms.jpg (GRAPHIC) — 303KB
- a2024_annualxshareholderxmt.jpg (GRAPHIC) — 332KB
- a2024_annualxshareholderxmu.jpg (GRAPHIC) — 76KB
- a2024_annualxshareholderxmv.jpg (GRAPHIC) — 244KB
- a2024_annualxshareholderxmw.jpg (GRAPHIC) — 210KB
- a2024_annualxshareholderxmx.jpg (GRAPHIC) — 350KB
- a2024_annualxshareholderxmy.jpg (GRAPHIC) — 691KB
- a2024_annualxshareholderxmz.jpg (GRAPHIC) — 124KB
- a2024defa14a-additionalmat.jpg (GRAPHIC) — 218KB
- a2024defa14a-additionalmata.jpg (GRAPHIC) — 306KB
- 0001299130-24-000127.txt ( ) — 5502KB
From the Filing
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to 240.14a-12 Pacific Biosciences of California, Inc. (Name of Registrant as Specified In Its Charter) Payment of Filing Fee (Check the appropriate box) No fee required Fee paid previously with preliminary materials Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11